Evolus, Inc.

Evolus is a medical aesthetics company focused on providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures.Evolus’ primary market is self-pay healthcare. Our lead product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.Evolus, Inc., incorporated on November 9, 2012, is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large and growing facial aesthetics market. It offers physicians and patients a compelling value proposition with DWP-450. OnabotulinumtoxinA (BOTOX) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.

Bank Name Evolus, Inc.
Stock Exchange NASDAQ
Symbol EOLS
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
Chairman
CEO Dr. Rui Avelar M.D.
Employees 24
Website www.evolus.com
Registered Year 2012

UpdateContent
UpdateContent
UpdateContent